Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (CheckMate76K)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04099251 |
Recruitment Status :
Active, not recruiting
First Posted : September 23, 2019
Results First Posted : July 27, 2023
Last Update Posted : November 14, 2023
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Melanoma | Biological: Nivolumab Other: Placebo | Phase 3 |
Expanded Access : An investigational treatment associated with this study has been approved for sale to the public. More info ...
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 790 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy With Nivolumab Versus Placebo After Complete Resection of Stage IIB/C Melanoma |
Actual Study Start Date : | October 28, 2019 |
Actual Primary Completion Date : | June 28, 2022 |
Estimated Study Completion Date : | June 29, 2027 |
Arm | Intervention/treatment |
---|---|
Experimental: Nivolumab |
Biological: Nivolumab
Specified dose on specified days
Other Name: Opdivo |
Placebo Comparator: Placebo |
Other: Placebo
Specified dose on specified days |
- Recurrence Free Survival (RFS) [ Time Frame: From randomization up to the date of first recurrence, new primary melanoma, or death (whatever the cause), whichever occurs first (up to 32 months) ]Recurrence Free Survival (RFS) is defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (whatever the cause), whichever occurs first. For participants who remain alive and whose disease has not recurred or did not die, RFS will be censored on the date of last evaluable disease assessment. For those participants who remained alive and had no recorded post-randomization tumor assessment, RFS will be censored on the day of randomization.
- Distant Metastasis-Free Survival (DMFS) [ Time Frame: From randomization up to the date of first distant metastasis or date of death (whatever the cause), whichever occurs first (up to approximately 32 months) ]Investigator-assessed distant metastasis-free survival (DMFS) is defined as the time between the date of randomization and the date of first distant metastasis or date of death (whatever the cause), whichever occurs first. Participants with no baseline disease assessment, no on-study disease assessments and no death, and no distant metastasis and no death will be censored. Participants with no baseline disease assessment and no on-study disease assessments and death are censored on the date of randomization. Participants with no recurrence and no death will be censored on the date of their last evaluable disease assessment.
- Duration of Treatment on Next Line Therapy Per Investigator Assessment [ Time Frame: From first dose date of next-line therapy to last dose date of next-line therapy (up to approximately 32 months) ]Duration of treatment is an investigator-assessed outcome of next-line therapy (NLT) defined as the time from first dose date of NLT to last dose date of NLT. Participants who did not stop the NLT were censored.
- Progression-Free Survival Through Next-Line Therapy [ Time Frame: From randomization to recurrence/objective disease progression after the start of the next-line therapy, or to the start of a second next-line systemic therapy, or to death from any cause, whichever occurs first (up to approximately 32 months) ]Progression-free survival through next-line therapy (PFS2) is defined as the time from randomization to recurrence/objective disease progression after the start of the next-line of systemic anti-cancer therapy, or to the start of a second next-line systemic therapy, or to death from any cause, whichever occurs first. Participants who did not receive subsequent systemic anti-cancer therapy who died will be considered as having the event on the date of death. Participants who received subsequent systemic anti-cancer therapy who had a disease progression after the start of therapy will be considered as having the event on the date of disease progression. Participants who died or started second next-line therapy, the date of death or start date of second next-line therapy will be the event date, whichever is earlier. Participants who did not experience disease progression, death, or second next-line therapy will be censored on the last known alive date.
- Number of Participants Experiencing Adverse Events (AEs) [ Time Frame: From first dose up to 30 days post last dose of the blinded phase (up to 13 months) ]An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
- Number of Participants Experiencing Adverse Events Leading to Discontinuation [ Time Frame: From first dose up to 30 days post last dose of the blinded phase (up to 13 months) ]An Adverse Event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure.
- Number of Participants Experiencing Select Adverse Events [ Time Frame: From first dose up to 30 days post last dose of the blinded phase (up to 13 months) ]The number of participants experiencing all-cause select adverse events (AEs). An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure.
- Number of Participants Experiencing Serious Adverse Events (SAEs) [ Time Frame: From first dose up to 30 days post last dose of the blinded phase (up to 13 months) ]A Serious Adverse Events (SAE) is defined as any untoward or unfavorable medical occurrence in a participants that results in death, is life threatening, or places the participant at immediate risk of death from the event as it occurred, requires or prolongs hospitalization, causes persistent or significant disability or incapacity, results in congenital anomalies or birth defects, and is another condition which investigators judge to represent significant hazards.
- Number of Participants Experiencing Death [ Time Frame: From first dose up to 30 days post last dose of the blinded phase (up to 13 months) ]All study participants who died during the blinded phase of the study following treatment.
- Number of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities in Selected Hematology Parameters [ Time Frame: From first dose up to 30 days post last dose of the blinded phase (up to 13 months) ]The number of participants experiencing Grade 3 or 4 laboratory abnormalities in the specific pre-determined hematology tests.
- Number of Participants Experiencing Laboratory Abnormalities in Selected Liver Parameters [ Time Frame: From first dose up to 30 days post last dose of the blinded phase (up to 13 months) ]The number of participants experiencing laboratory abnormalities in the specific pre-determined liver tests.
- Overall Survival (OS) [ Time Frame: From randomization up to the date of death or the last date the participant was known to be alive ]OS is defined as the time between the date of randomization and the date of death. For those without documentation of death, OS will be censored on the last date the participant was known to be alive.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Had a negative sentinel lymph node biopsy
- Participant has not been previously treated for melanoma
- ECOG 0 or 1
- Participants must have been diagnosed with histologically confirmed, Resected, Stage IIB/C cutaneous melanoma
Exclusion Criteria:
- History of ocular or mucosal melanoma.
- Pregnant or nursing women
- Participants with active known or suspected autoimmune disease
- Known history of allergy or hypersensitivity to study drug components
- Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody, or agents that target IL-2 pathways, T-cell stimulators, or checkpoint pathways
Other protocol defined inclusion/exclusion criteria apply.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04099251
Study Director: | Bristol-Myers Squibb | Bristol-Myers Squibb |
Documents provided by Bristol-Myers Squibb:
Responsible Party: | Bristol-Myers Squibb |
ClinicalTrials.gov Identifier: | NCT04099251 |
Other Study ID Numbers: |
CA209-76K 2019-001230-34 ( EudraCT Number ) U1111-1229-8927 ( Other Identifier: UTN Number ) |
First Posted: | September 23, 2019 Key Record Dates |
Results First Posted: | July 27, 2023 |
Last Update Posted: | November 14, 2023 |
Last Verified: | November 2023 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Nerve Tissue Nevi and Melanomas |
Skin Neoplasms Neoplasms by Site Skin Diseases Nivolumab Antineoplastic Agents, Immunological Antineoplastic Agents Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action |